| Business Summary | | UroCor,
Inc.
markets
a
comprehensive
range
of
products
and
services
to
assist
in
detecting,
diagnosing,
treating
and
managing
prostate
cancer,
bladder
cancer,
kidney
stones
and
other
complex
urologic
disorders.
The
Company's
primary
focus
is
providing
products
and
services
to
help
urologists
improve
patient
care
and
outcomes
while
reducing
the
total
cost
of
managing
these
diseases.
The
Company
provides
comprehensive
diagnostic
services
to
detect
major
urologic
conditions,
enhance
the
accuracy
of
prognosis
of
individual
patient's
disease,
monitor
the
patient's
therapy
and
identify
recurrence
of
the
disease.
UroCor
also
performs
research
and
development
work,
pursuant
to
which
it
develops,
evaluates
and
customizes
new
diagnostic
products
and
technologies
for
use
in
its
diagnostic
service
offerings.
In
addition,
the
Company
facilitates
the
development
and
utilization
of
its
disease
databases
and
related
information
systems. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | UCOR
provides
diagnostic
services
for
the
clinical
management
of
certain
urological
cancers
and
diseases,
and
provides
information
services
and
therapeutic
products
to
urologists
and
HMOs.
For
the
six
months
ended
6/30/01,
revenues
increased
29%
to
$31.3
million.
Net
income
rose
from
$865
thousand
to
$4.7
million.
Revenues
reflect
the
price
increase
on
diagnostic
services
and
the
marketing
of
ProstaSeed.
Earnings
benefited
from
the
gain
on
termination
of
therapeutic
agrmt. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Herbert Conrad, 68 Chairman | -- | Michael George, 52 Pres,
CEO, Director | $260K | Bruce Hayden, 40 CFO,
Sr. VP, Sec., Treasurer | 193K | Karl Nigg, 43 Sr.
VP- Operations | 205K | Melissa Walker, 39 VP,
CCO | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|